Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIM1U9)

• Drug Name: Vorolanib Drug Info
• Synonyms: UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-

Indication

Disease Entry	ICD 11	Status	REF
Non-small cell lung cancer	2C25	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 59215954
  CAS Number: CAS 1013920-15-4
  TTD Drug ID: DMIM1U9

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor (VEGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[3]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[4]
Fruquintinib	DMHOSCQ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
KH-902	DM8VO16	Diabetic macular edema	9B71.02	Phase 3	[5]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[7]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[4]
BFH-772	DMVUX1C	Psoriasis vulgaris	EA90	Phase 2	[8]
ASP-8477	DMBZQS7	Neuropathic pain	8E43.0	Phase 2	[9]
AG-013958	DMRET3H	Age-related macular degeneration	9B75.0	Phase 1/2	[10]

Drug(s) Targeting Platelet-derived growth factor receptor (PDGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[11]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[12]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[3]
CT-102	DMB8PF3	Diabetic foot ulcer	BD54	Approved	[13]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[14]
Rosiglitazone + metformin	DMPIDXT	Diabetic complication	5A2Y	Phase 3	[11]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[11]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[11]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[15]
PMID25623274-Compound-WO2014132220C2	DMXEZWP	Pulmonary arterial hypertension	BB01.0	Patented	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Inhibitor	[2]
Vascular endothelial growth factor receptor (VEGFR)	TTVJ1D8	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03848611) CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).. U.S. National Institutes of Health.
• [2] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
• [6] National Cancer Institute Drug Dictionary (drug id 452042).
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] CA patent application no. 841416, Method of selecting therapeutic indications.
• [9] ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
• [10] Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933.
• [11] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [12] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [13] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [14] Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
• [15] National Cancer Institute Drug Dictionary (drug id 695817).
• [16] Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.